TipRanks
Advertisement
Advertisement
Adial Pharmaceuticals Faces Nasdaq Listing Compliance Challenge
PremiumCompany AnnouncementsAdial Pharmaceuticals Faces Nasdaq Listing Compliance Challenge
2M ago
Is ADIL a Buy, Before Earnings?
Premium
Pre-Earnings
Is ADIL a Buy, Before Earnings?
2M ago
Adial Pharma Faces Governance Risks and Major Dilution as 2026 Shareholder Vote Looms on Preferred Conversions and Warrants
Premium
Company Announcements
Adial Pharma Faces Governance Risks and Major Dilution as 2026 Shareholder Vote Looms on Preferred Conversions and Warrants
2M ago
Adial Pharmaceuticals announces acquisition of Azora Therapeutics
PremiumThe FlyAdial Pharmaceuticals announces acquisition of Azora Therapeutics
4M ago
Adial Pharmaceuticals: Buy Rating Reiterated as AD04’s Precision AUD Strategy Advances; $8 Price Target Maintained
Premium
Ratings
Adial Pharmaceuticals: Buy Rating Reiterated as AD04’s Precision AUD Strategy Advances; $8 Price Target Maintained
5M ago
Adial Pharma’s Strategic Options: High-Stakes Search for a Deal Puts Share Price and Long-Term Prospects at Risk
Premium
Company Announcements
Adial Pharma’s Strategic Options: High-Stakes Search for a Deal Puts Share Price and Long-Term Prospects at Risk
5M ago
Adial Pharmaceuticals expects cash to fund operations into 2H of 2026
PremiumThe FlyAdial Pharmaceuticals expects cash to fund operations into 2H of 2026
7M ago
Adial Pharmaceuticals Secures European Partnership for AD04 Commercialization
Premium
Company Announcements
Adial Pharmaceuticals Secures European Partnership for AD04 Commercialization
7M ago
Adial Pharmaceuticals enters collaboration framework agreement with Molteni
Premium
The Fly
Adial Pharmaceuticals enters collaboration framework agreement with Molteni
7M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―